Loading...
Targeting DDX3X Helicase Activity with BA103 Shows Promising Therapeutic Effects in Preclinical Glioblastoma Models
Brai, Annalaura Riva, Valentina Clementi, Letizia Falsitta, Lucia Zamperini, Claudio Sinigiani, Virginia Festuccia, Claudio Sabetta, Samantha Aiello, Davide Roselli, Camilla
Brai, Annalaura
Riva, Valentina
Clementi, Letizia
Falsitta, Lucia
Zamperini, Claudio
Sinigiani, Virginia
Festuccia, Claudio
Sabetta, Samantha
Aiello, Davide
Roselli, Camilla
Citations
Altmetric:
Genre
Journal article
Date
2021-11-07
Advisor
Committee member
Department
Biology
Permanent link to this record
Collections
Research Projects
Organizational Units
Journal Issue
DOI
https://doi.org/10.3390/cancers13215569
Abstract
DDX3X is an ATP-dependent RNA helicase that has recently attracted interest for its involvement in viral replication and oncogenic progression. Starting from hit compounds previously identified by our group, we have designed and synthesized a new series of DDX3X inhibitors that effectively blocked its helicase activity. These new compounds were able to inhibit the proliferation of cell lines from different cancer types, also in DDX3X low-expressing cancer cell lines. According to the absorption, distribution, metabolism, elimination properties, and antitumoral activity, compound BA103 was chosen to be further investigated in glioblastoma models. BA103 determined a significant reduction in the proliferation and migration of U87 and U251 cells, downregulating the oncogenic protein β-catenin. An in vivo evaluation demonstrated that BA103 was able to reach the brain and reduce the tumor growth in xenograft and orthotopic models without evident side effects. This study represents the first demonstration that DDX3X-targeted small molecules are feasible and promising drugs also in glioblastoma.
Description
Citation
Brai A, Riva V, Clementi L, Falsitta L, Zamperini C, Sinigiani V, Festuccia C, Sabetta S, Aiello D, Roselli C, Garbelli A, Trivisani CI, Maccari L, Bugli F, Sanguinetti M, Calandro P, Chiariello M, Quaranta P, Botta L, Angelucci A, Maga G, Botta M. Targeting DDX3X Helicase Activity with BA103 Shows Promising Therapeutic Effects in Preclinical Glioblastoma Models. Cancers. 2021; 13(21):5569. https://doi.org/10.3390/cancers13215569
Citation to related work
MDPI
Has part
Cancers, Vol. 13, No. 21
ADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu